NEW STUDY: Antioxidant & anti-inflammatory properties identified in CyaninPlus, according to new research
May 19, 2015Klamath Falls, Oregon
As recently published in the Journal of Medicinal Food, Jensen et al. set out to characterize the basic biological properties of CyaninPlus, which contains a known anti-inflammatory cyclooxygenase-2 (COX-2) inhibitor phycocyanin (PC), as well as a high level of non- phycocyanin bioactive compounds. While quite a few of the observed effects were attributed to the phycocyanin component of CyaninPlus, the results indicate that the non- phycocyanin components were equally important to CyaninPlus’s efficacy. The overall conclusions of the study suggest that the natural synergy of the phycocyanin and non- phycocyanin components provide superior nutritional support against chronic inflammatory conditions.
CyaninPlus’s antioxidant properties were tested in parallel in the Folin-Ciocalteu assay (chemical antioxidant capacity) and in the cellular antioxidant protection (CAP-e) bioassay, where both the phycocyanin and the non- phycocyanin fractions contributed to the antioxidant capacity and cellular antioxidant protection of CyaninPlus. CyaninPlus was also tested for its ability to inhibit the inflammatory enzymes COX-2 and Lipoxygenase. Results indicate that CyaninPlus offers a synergistic inhibition of both enzymes. The formation of reactive oxygen species (ROS) was evaluated using polymorphonuclear cells from healthy human donors. The inhibition of ROS formation was observed in both the PC and non- phycocyanin fractions, with the most robust effect being observed by the introduction of CyaninPlus.
Interestingly, an important observation pertaining to product safety was made. Other research teams have previously suggested that phycocyanin may have value as a blood thinning agent, as phycocyanin can, under some laboratory conditions, lead to reduced platelet aggregation, platelet activation, and platelet membrane fluidity. NIS Labs researcher, Dr. Jensen, explained “We feel that this interpretation may be too simplistic of an explanation. Previously reported effects of phycocyanin on isolated blood platelets may possibly be a downstream effect of initial anti-inflammatory events.” The study findings suggest that the presence of CyaninPlus and phycocyanin in the Euglobulin fraction when triggering fibrin clotting led to stronger (not weaker) clot formation, whereas the following natural fibrinolytic clot dissolution happened at normal rate.
The full study, entitled “Antioxidant and Anti-Inflammatory Properties of an Aqueous Cyanophyta Extract Derived from Arthrospira Platensis: Contribution to Bioactivities by the Non-Phycocyanin Aqueous Fraction”, is available at: liebertpub.com »
“This and other studies show that supplementation with CyaninPlus can lead to a clinically meaningful effect as an antioxidant and anti-inflammatory alternative,” said Cassandra Drapeau, Product Manager from Desert Lake Technologies, the developer and manufacturer of CyaninPlus. “The natural synergy of the phycocyanin and non- phycocyanin compounds help balance and calm inflammation without the known side effects of nonsteroidal anti-inflammatory drugs.”
Desert Lake Technologies® is a trusted provider and creator of “Algaceuticals™”, a new category of scientifically researched, high-quality, microalgae ingredients, which apply the bioactive properties of microalgae to promote and restore human health. Desert Lake Technologies is a family-owned business with a 16-year history as a manufacturer committed to research, innovation and delivering proven results. Desert Lake Technologies is based in Klamath Falls, Oregon. For more information, please visit www.desertlake.com.